This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda. “This continuing agreement with ...

Single intrathecal dose of Rhenium (186 Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation ...

IsoTherapeutics', a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics' lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda.

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE ...

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Plus ...

(‘IsoTherapeutics’, a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda. ...

The data were presented in a session titled, “Rhenium (186 Re) Obisbemeda (rhenium nanoliposome, 186 RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented ...